ABCG2 regulates the pattern of self-renewing divisions in cisplatin-resistant non-small cell lung cancer cell lines

被引:33
作者
Tang, Ying [1 ]
Hou, Jingming [2 ]
Li, Guanghui [1 ]
Song, Zongchang [1 ]
Li, Xiaojing [1 ]
Yang, Cui [1 ]
Liu, Wenying [1 ]
Hu, Yide [1 ]
Xu, Yu [3 ]
机构
[1] Third Mil Med Univ, Xinqiao Hosp, Dept Oncol, Chongqing 400038, Peoples R China
[2] Chinese PLA Beijing Army Gen Hosp, Dept Orthoped, Beijing 100700, Peoples R China
[3] Third Mil Med Univ, Inst Resp Dis, Xinqiao Hosp, Chongqing 400038, Peoples R China
基金
中国国家自然科学基金;
关键词
ABCG2; drug resistance; NSCLC; symmetric division; asymmetric division; MULTIDRUG-RESISTANCE; STEM-CELLS; ASYMMETRIC DIVISION; DRUG-RESISTANCE; IN-VIVO; EXPRESSION; CHEMOTHERAPY; TRANSPORTER; SUPPRESSION; PHENOTYPE;
D O I
10.3892/or.2014.3470
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Overexpression of ABCG2 is considered a major mechanism of cancer drug resistance. Recent studies have shown that ABCG2 can regulate the switch between symmetric and asymmetric cell division in adult stem cells; however, the relationship between ABCG2 and cell division in drug-resistant cancer cells remains to be determined. In the present study, we demonstrated that ABCG2 is involved in the cell division of drug-resistant cancer cells. We first established drug-resistant H460 and A549 cell lines by repeated exposure to cisplatin and found that the expression of ABCG2 in these cell lines was significantly increased. As evidenced by PKH-26 staining, these drug-resistant cell lines favored symmetric division, which differed from the asymmetric division of the parental cells. Furthermore, we established stable ABCG2-overexpressing and stable shRNA-ABCG2-knock-down cell lines to evaluate the potential role of ABCG2 in cancer cell division. The results showed that overexpression of ABCG2 in A549 parental cells significantly increased the proportion of symmetric division, whereas knockdown of ABCG2 in drug-resistant A549 cells significantly increased the proportion of asymmetric division. Taken together, our findings suggest that ABCG2 is involved in the modulation of cancer drug resistance by regulating the pattern of cell division. The present study provides novel insight into the role of ABCG2 in cancer treatment resistance.
引用
收藏
页码:2168 / 2174
页数:7
相关论文
共 50 条
[41]   Metformin enhances the radiosensitizing effect of cisplatin in non-small cell lung cancer cell lines with different cisplatin sensitivities [J].
Riaz, Muhammad Assad ;
Sak, Ali ;
Erol, Yasin Bahadir ;
Groneberg, Michael ;
Thomale, Jurgen ;
Stuschke, Martin .
SCIENTIFIC REPORTS, 2019, 9 (1)
[42]   Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin [J].
Ceppi, Paolo ;
Papotti, Mauro ;
Monica, Valentina ;
Lo Iacono, Marco ;
Saviozzi, Silvia ;
Pautasso, Marisa ;
Novello, Silvia ;
Mussino, Stefano ;
Bracco, Enrico ;
Volante, Marco ;
Scagliotti, Giorgio V. .
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (11) :3066-3074
[43]   Pemetrexed-Resistant Non-Small Cell Lung Cancer Cell Lines Have Novel Drug-Resistant Mechanisms [J].
Tanino, R. ;
Tsubata, Y. ;
Harashima, N. ;
Harada, M. ;
Isobe, T. .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :S1949-S1949
[44]   Lentinan combined with cisplatin for the treatment of non-small cell lung cancer [J].
Zhao, Chenchen ;
Yan, Haifeng ;
Pang, Wentai ;
Wu, Tong ;
Kong, Xianbin ;
Li, Xiaojiang ;
Liu, Honggen ;
Zhao, Linlin ;
Liang, Feng ;
Jia, Yingjie .
MEDICINE, 2021, 100 (12)
[45]   Precision-engineered reporter cell lines reveal ABCG2 regulation in live lung cancer cells [J].
Kovacsics, Daniella ;
Brozik, Anna ;
Tihanyi, Borbala ;
Matula, Zsolt ;
Borsy, Adrienn ;
Meszaros, Nikolett ;
Szabo, Edit ;
Nemeth, Eszter ;
Fothi, Abel ;
Zambo, Boglarka ;
Szuts, David ;
Varady, Gyorgy ;
Orban, Tamas, I ;
Apati, Agota ;
Sarkadi, Balazs .
BIOCHEMICAL PHARMACOLOGY, 2020, 175
[46]   A novel camptothecin analogue FL118 reduces cisplatin resistance of non-small cell lung cancer cells [J].
Zhang, Dandan ;
Wang, Jin ;
Yang, Zhihong ;
Liu, Jia ;
Liu, Zhantao ;
Ji, Lixia ;
Liu, Ranran ;
Lin, Qian ;
Jiang, Guohui .
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (07) :13501-13513
[47]   Silencing Nrf2 in cisplatin resistant non-small cell lung cancer cells augments sensitivity towards EGFR inhibitor [J].
Fouzder, Chandrani ;
Mukhuty, Alpana ;
Chattopadhyay, Dipanjan ;
Das, Snehasis ;
Hira, Sumit Kumar ;
Kundu, Rakesh .
TOXICOLOGY IN VITRO, 2024, 101
[48]   A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer [J].
Ramisetty, Sravani ;
Kulkarni, Prakash ;
Bhattacharya, Supriyo ;
Nam, Arin ;
Singhal, Sharad S. ;
Guo, Linlin ;
Mirzapoiazova, Tamara ;
Mambetsariev, Bolot ;
Mittan, Sandeep ;
Malhotra, Jyoti ;
Pisick, Evan ;
Subbiah, Shanmuga ;
Rajurkar, Swapnil ;
Massarelli, Erminia ;
Salgia, Ravi ;
Mohanty, Atish .
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (02)
[49]   MiR-130a Overcomes Gefitinib Resistance by Targeting Met in Non-Small Cell Lung Cancer Cell Lines [J].
Zhou, Yong-Ming ;
Liu, Juan ;
Sun, Wei .
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (03) :1391-1396
[50]   The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas [J].
Li, Feng ;
Zeng, Huazong ;
Ying, Kejing .
MEDICAL ONCOLOGY, 2011, 28 (04) :1458-1462